Breast cancer of different subtypes may have significantly distinct prognosis, different therapeutic strategies and marked difference in survival.10–12 Patients with triple-negative breast cancer cannot benefit from the targeted endocrine therapy and anti-HER-2 treatment. This evidence concerns the gene ERBB2 and breast carcinoma.